Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » About Us » Our Staff » Turna Ray

Turna Ray

Managing Editor, Precision Oncology News
Phone Number
+1-212-651-5626
Email
[email protected]
Turna Ray at Genomeweb / 360dx Turna Ray at Genomeweb / 360dx

Turna Ray has been covering the personalized medicine and molecular diagnostics industries for GenomeWeb since 2006. She closely tracks the evolving regulatory, reimbursement, and business environment for precision medicine products. 

Articles Authored by Turna Ray

Aug 28, 2020

Stakeholders Scramble to Predict Impact of HHS Move Limiting FDA Ability to Regulate LDTs

Premium

The move raises questions about what precisely is an LDT outside of FDA jurisdiction and heightens concerns that poorly validated tests will enter the market and endanger public health.

Jun 04, 2020

Studies Show Potential of Video, Online Education to Expand Cancer Risk Genetic Test Access

Premium

The MAGENTA and ProGen trials showed that video-based and online education can increase the number of patients getting tested compared to traditional approaches.  

May 31, 2020

Germline Results From Tumor-Normal Sequencing Guides Precision Therapy in Advanced Cancer Patients

Two studies presented at ASCO's virtual annual meeting demonstrated the clinical utility of germline findings in guiding treatment decisions in cancer.

May 29, 2020

Patients Having Ovaries Removed Without Clear Genetic, Medical Rationale, Study Suggests

Premium

Results from the PROMPT registry presented at ASCO showed that 10 to 15 percent of women with variants in genes not linked to ovarian cancer had oophorectomies.

May 21, 2020

Q&A: ACMG Work Group Hoping to Spark Discussion on Reporting Germline Findings From Tumor Testing

In an interview, Marilyn Li and Douglas Stewart discuss why ACMG has put forth points that doctors and labs should consider when presumed germline findings crop up in tumor testing.

Apr 27, 2020

Amid COVID-19, Lower Cancer Diagnosis Rates Mean Fewer Patients Getting Molecular Tests, Treatment

Premium

Data amassed by analytics firm Diaceutics suggests fewer patients are coming into healthcare facilities and missing the chance for diagnosis, molecular testing, and treatment.

Apr 24, 2020

Amid COVID-19 Therapeutic Uncertainty, Experts Look for Potential Role for PGx in Managing Meds

Premium

The available data suggests PGx may be useful in managing medications for COVID-19 patients and in helping people struggling with the mental health impact of the pandemic.

Apr 19, 2020

Despite FDA Guidance, CDx Providers Still Have Challenges in Seeking 'Therapeutic Group' Indication

Premium

While the guidance may lead to more streamlined CDx indications in precision oncology, test developers will still need to generate evidence, perhaps with limited pharma support.

Apr 14, 2020

Merck Bid for Second Pan-Cancer Keytruda Indication Would Raise Tumor Mutation Burden to CDx Status

Premium

With TMB as a CDx, the drug will be available to more patients as a salvage option, but doctors will still need to consider the complex biomarker amid evolving research.

Mar 31, 2020

Color Gears Up to Enter COVID-19 Testing Space

Color is opening a lab dedicated to SARS-CoV-2 testing and adapting its software infrastructure to enable physicians to order tests and return results.

The Scan

This Time, Novavax

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

Shortened Visas for Some Students

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

New York's Own Review

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

Science Papers Examine Y Chromosomes of Archaic Humans, Schistosomiasis Therapeutic Targets

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.